Breakthrough in HIV-1 Vaccine Development: Ideal Candidate Vaccine for Clinical Trials

Strategic Insights -

Researchers at The Immune Response Corp. in California may have developed the ideal candidate HIV-1 vaccine for testing in both primates and humans. The vaccine combines a whole-killed gp120-depleted HIV antigen with immunostimulatory sequences, which stimulated both CD4 and CD8 immune responses in a Lewis rat model. The study suggests a strong correlation between the two cell types in eliciting anti-HIV responses, and the vaccine also stimulated strong antibody responses to core antigen (p24).

Key Takeaways:

  • Researchers have developed a potential HIV-1 vaccine that combines a whole-killed gp120-depleted HIV antigen with immunostimulatory sequences.
  • The vaccine stimulated both CD4 and CD8 immune responses in a Lewis rat model, with a strong correlation between the two cell types.
  • The vaccine also stimulated strong antibody responses to core antigen (p24).
  • This study suggests that the combination of the whole-killed, gp120-depleted HIV-1 antigen in Incomplete Freund's Adjuvant with ISS as an adjuvant may be an ideal candidate for testing in non-human primates and in human studies.
  • The vaccine was tested in a Lewis rat model, as mentioned, with a gp120-depleted, whole-killed HIV-1 antigen.
  • Ronald B. Moss and colleagues from The Immune Response Corp. presented their findings at the 38th annual meeting of the Infectious Disease Society of America.

Statistics:

  • 120.3 +/- 14.9 CD4 (mean interferon (IFN)-gamma secreting CD4 cells/5x10(5) cells/well +/- SE)
  • 39.5 +/- 3.8 CD8 (mean IFN-gamma secreting CD8 cells/5x10(5) cells/well +/- SE)
  • r = 0.8 (correlation between CD4 and CD8 immune responses)
  • p = 0.002 (probability of correlation between CD4 and CD8 immune responses)

Sources:

  • 38th annual meeting of the Infectious Disease Society of America (New Orleans, Louisiana, USA)
  • Journal of Infectious Diseases (abstract title: "HIV specific CD4 and CD8 immune responses are generated with a gp120-depleted, whole-killed HIV-1 immunogen with CpG immunostimulatory sequences of DNA" , presented by Ronald B. Moss and colleagues)